Actively Recruiting
Observational Study on Intravenous Vonicog Alfa rVWF in Children with Von Willebrand Disease in Japan
Led by Takeda · Updated on 2026-02-23
13
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating vonicog alfa rVWF for treating children with Von Willebrand Disease vWD in Japan. The study aims to assess both the safety, focusing on adverse drug reactions, and the effectiveness of rVWF in pediatric patients. This observational study records how the drug is used during routine care without altering standard treatment practices. Participants with vWD will receive vonicog alfa rVWF via intravenous injection as prescribed for managing bleeding episodes or during surgical procedures. The drug administration follows standard practice according to the approved package insert, and the study sponsor does not influence treatment decisions. The observation period for each participant lasts up to one year from the start of rVWF administration. During the study, researchers will monitor and document any adverse drug reactions and evaluate hemostatic effectiveness using a rating scale over one year. They will also track the number of infusions used per bleeding episode and during surgeries. Participants will be observed through their routine clinical visits, and the study will collect data on safety and treatment outcomes throughout this period.
CONDITIONS
Brief Title
An Observational Study of Vonicog Alfa (rVWF) in Pediatric Participants With Von Willebrand Disease (vWD)
Research Team
T
Takeda Contact
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here